Sachiyo Minegishi
Geen lopende functies
Profiel
Sachiyo Minegishi worked as a Senior Director at Aegerion Pharmaceuticals, Inc. from 2012 to 2016, and as a Vice President at bluebird bio, Inc. from 2016 to 2020.
She also worked as the Head of Finance at Akouos, Inc. Ms. Minegishi completed her undergraduate degree at the Massachusetts Institute of Technology and earned an MBA from The Wharton School of the University of Pennsylvania.
Eerdere bekende functies van Sachiyo Minegishi
Bedrijven | Functie | Einde |
---|---|---|
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01-09-2020 |
AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-04-2016 |
AKOUOS | Director of Finance/CFO | - |
Opleiding van Sachiyo Minegishi
Massachusetts Institute of Technology | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Akouos, Inc.
Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |